# Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

> **NCT04882163** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Celgene**

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** CC-220
- **DRUG:** Polatuzumab vedotin
- **DRUG:** Rituximab
- **DRUG:** Tafasitamab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Dexamethasone
- **DRUG:** Bendamustine
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT04882163
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-10
- **Primary completion:** 2026-04-08
- **Final completion:** 2029-04-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882163, "Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04882163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*